Publication Archive

 

 

This archive contains all documents published by cep over the last few years:

cepAdhoc: Incisive comment on current EU policy issues

cepPolicyBrief: Concise reviews of EU proposals (Regulations, Directives, Green Papers, White Papers, Communications) – including an executive summary

cepInput: Impulse to current challenges of EU policies

cepStudy: Comprehensive examination of EU policy proposals affecting the economy

 

 

2020

The COVID 19 crisis and its serious consequences for the economy have led to a debate on the need to protect EU companies from being taken over by foreign investors. Consequently, the EU Commission has published guidance on how to deal with investments from third countries. The cep has evaluated them.

2020

The "European Climate Law" aims to establish the objective of EU "climate neutrality" by 2050 as well as the assessment of a further tightening of the emission reduction requirements for 2030 from 40% to 50% - 55% as compared with 1990 levels.

2020

The EU Commission has submitted a "strategic approach" aimed at reducing pharmaceutical residues and their impact on the environment. The cep has analyzed and evaluated the Commission's communication on this issue.

2020

Following the uncoordinated and in some cases arbitrary closure of national borders as a result of the Corona crisis, the EU Commission has published Guidelines to better coordinate entry restrictions at the internal market borders. In doing so, the EU Commission relies on the cooperation of the Member States. The cep has evaluated the guidelines.

2020

Contact tracing apps will play an important role in the fight against the Coronavirus. The cepAdhoc illustrates the EU privacy and personal data protection framework applicable to them.

2020

On the basis of the Transparency Regulation, the CJEU has for the first time decided on third party access to documents submitted to the European Medicines Agency (EMA) by pharmaceutical companies. A cepInput explains the background and relevance of the CJEU proceedings and deals with the three main grounds for the decision in the "PTC Therapeutics" judgement.